The choices, attitudes, and experience of medical cannabis patients in Illinois will be documented in a first-of-its-kind study through January 8.
Revolution Cannabis Analytics, a newly formed division of Revolution Enterprises, an Illinois-based company that manages two state-of-the-art cannabis cultivation and laboratory facilities in Central Illinois, will perform the study.
Revolution Enterprises said it formed Revolution Cannabis Analytics "to better understand the unique effects of cannabinoids and the types of relief they may provide to patients suffering from certain conditions." Certain cannabinoids, a class of compounds found in the cannabis plant, may be beneficial in the treatment of various health conditions, according to a growing body of research.
Illinois, which allowed for the first sales of legal cannabis Nov. 9, has 3,600 registered patients for the state's pilot program, according to the Illinois Department of Public Health. In addition, almost 29,300 persons with debilitating conditions have started the patient application process since IDPH began accepting applications on Sept. 2, 2014, data show.
"By using information captured through Revolution Cannabis Analytics, we will create the next generation of Revolution genetic varieties to precisely address specific debilitating conditions," said Revolution Enterprises CEO Tim McGraw. "This program will help Illinois to lead the world in the collection of analytical data and patient feedback as it relates to the science of cannabis."